Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Switch Case Study: GSK Alli Review Shows FDA Data Mining In Context

This article was originally published in The Tan Sheet

Executive Summary

[F-D-C Reports' Pharmaceutical Approvals Monthly dissects drug reviews by FDA. While each drug stands or fails alone, a specific review can provide valuable insight into FDA's interpretation of data, policy and guidance documents, recurring controversies and resolution of internal disagreement. This story completes a two-part feature on alli.
Advertisement

Related Content

Sea Changes In Regulation And The Market: Top Stories Of 2008
Sea Changes In Regulation And The Market: Top Stories Of 2008
Sea Changes In Regulation And The Market: Top Stories Of 2008
FDA “Safety First” Initiative, Agency’s Requests Draw Doubts From DeLauro
Alli Approved OTC For Weight Loss With “Goal Oriented” Indication
Alli Approved OTC For Weight Loss With “Goal Oriented” Indication
Glaxo’s Alli Advances Toward OTC Sale With “Approvable” Letter

Topics

Advertisement
UsernamePublicRestriction

Register

PS101855

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel